QNRX QUOIN PHARMACEUTICALS LTD

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live call can also be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call may be accessed on the Quoin Pharmaceuticals website under the Investors section:

.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit:  or LinkedIn for updates.

For further information, contact:

Investor Relations

PCG Advisory

Stephanie Prince



(646) 863-6341



EN
11/08/2022

Underlying

QNRXQUOIN PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOIN PHARMACEUTICALS LTD

 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivot...

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy. Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants...

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces that it has been granted Orphan Dru...

May 20, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index (CDLQI) all demonstrated improvement from baseline QRX003 is being well tolerated and no adverse events have been reportedPatient is expected to continue to be treated with QRX003 to assess progressCompany continues to advance ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Qu...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage, specialty pharmaceutical company focused on develop...

May 13, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results...

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and fina...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch